Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Clinical, genetic, and pathologic differences across race, ethnicity, and sex in patients with MDS and precursor conditions from the national MDS natural history study

View Full Paper
Ask AI
Bookmark
Share

Authors

CCChristelle ColinLZLing ZhangGAGregory A. Abel

Discussion

Loading...

Member takes

Overview

Analysis reveals significant differences in progression-free survival and TP53 mutations across race and sex in MDS patients.

Key Points

  • MDS patients with TP53 mutations experienced poorer progression-free survival, highlighting disparities in disease outcomes.
  • Statistical analyses indicated notable differences in MDS presentation and treatment across racial demographics, particularly for Black participants.
  • Logistic regression highlighted that older patients and those with higher risk disease had worse survival outcomes in the MDS cohort.
  • Differing treatment approaches and clinical outcomes in MDS underscore the relevance of genetic and demographic factors in patient care.

Cite This Study

Colin et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d831https://doi.org/10.1182/blood-2025-3845
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Myelodysplastic/myeloproliferative overlap neoplasms: Clinicopathological features, treatment strategies, and outcomes — a UK multicentre cohort Study2025
  2. 2Epidemiologic insights into early-onset myelodysplastic syndrome: A longitudinal SEER analysis (2000-2022)2025
  3. 3Molecular subclusters across the continuum of myelodysplastic neoplasms and acute myeloid leukaemia define distinct clinical entities2025
  4. 4Trends and disparities in myelodysplastic Syndrome–Associated mortality in the u.S. from 1999 to 2020: A population-based study using the CDC wonder database2025
  5. 5Racial disparities in genomic alterations and survival outcomes in Acute Myeloid Leukemia (AML)2025